[Maintenance strategies for advanced pancreatic cancer: Rationale and issues]

Bull Cancer. 2018 Sep;105(9):739-741. doi: 10.1016/j.bulcan.2018.06.009. Epub 2018 Jul 18.

[Article in French]

Authors

Anthony Turpin¹, Hortense Chevalier², Cindy Neuzillet³

Affiliations

¹ Hôpital Claude-Huriez, service d'oncologie médicale, rue Michel-Polonovski, 59037 Lille cedex, France; Université de Lille-Nord-de-France, Lille, France. Electronic address: anthony.turpin@chru-lille.fr.
² Université de Lille-Nord-de-France, Lille, France.
³ Institut Curie, département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France.

PMID: 30029762
DOI: 10.1016/j.bulcan.2018.06.009

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Drug Combinations
Fluorouracil / administration & dosage
Gemcitabine
Humans
Irinotecan
Leucovorin / administration & dosage
Maintenance Chemotherapy / methods*
Organometallic Compounds / administration & dosage
Oxaliplatin
Paclitaxel / administration & dosage
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / pathology
Randomized Controlled Trials as Topic

Substances

Drug Combinations
Organometallic Compounds
folfirinox
Oxaliplatin
Deoxycytidine
Irinotecan
Paclitaxel
Leucovorin
Fluorouracil
Camptothecin
Gemcitabine

Supplementary concepts

IFL protocol